Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/31/17 -- VistaGen Therapeutics, Inc.(NASDAQ:VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced the pricing of an underwritten public offering of 1,371,430 shares of its common stock and warrants to purchase up to 1,892,572 shares of common stock at an offering price of $1.75 per share and related warrants. Each share of common stock is being sold together with 1.0128 Series A1 Warrants and 0.3672 of a Series A2 Warrant, with each whole Series A1 Warrant and each whole Series A2 Warrant exercisable to purchase one whole share of common stock. The warrants have an exercise price of $1.82 per full share, and will terminate 5 years from the time each warrant is first exercisable. Series A1 Warrants to purchase up to 1,388,931 shares of common stock are not exercisable until 6 months after issuance. Series A2 Warrants to purchase up to 503,641 shares of common stock are immediately exercisable. The gross proceeds of the offering are expected to be approximately $2.4 million, before deducting the underwriting discount and other estimated offering expenses.
Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
http://m.nasdaq.com/press-release/vistagen-announces-pricing-of-underwritten-offering-of-common-stock-and-warrants-to-purchase-commo-20170831-00628
Hi C! I'll check out MRNS and tell you my thoughts. I recognize the focal seizure indication which means I likely checked it out some time ago so this may end up being a refresher. NVTR sounds really interesting. Thanks for that!
For psych play, I've been buying vtgn when it dips below 1.70 for the past year. And I bought a bunch of rlmd too. PIRS I sold a few weeks ago and bought back in at 4.46, think its gonna run a bit now so it'll be rinse and repeat for a while.
I'll get back to you here soon.
Take care!Hope you enjoy the rest of the summer!
Happy Fiday C!
Did you check out SYN's conf call? Riley sounded good, reality based. Goals are clear and streamlined with 004 immed priority and 010 backburner. I am glad to hear them state and maintain such clear purpose. For a tiny baby company, they were going in too many directions for a while there. Hyperfocus on 004, which is the reason I'm in this company, is smartest path.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.fda.gov/downloads/drugs/guidances/ucm153222.pdf&ved=0ahUKEwiJyOniurvVAhUGeCYKHVpOALgQFggtMAA&usg=AFQjCNFC16PagRtdo245UoTo9zSz8ozK7g
B. Type B Meeting
Type B meetings are as follows: 4
Pre-investigational new drug application (pre-IND) meetings (21 CFR 312.82)
Certain end-of-phase 1 meetings (21 CFR 312.82)
End-of-phase 2 and pre-phase 3 meetings (21 CFR 312.47)
Pre-new drug application/biologics license application meetings (21 CFR 312.47)
Type B meetings should be scheduled to occur within 60 days of FDA receipt of the written meeting request. If a sponsor or applicant requests a meeting date that is beyond 60 days from the date of request receipt, we will work with the sponsor or applicant to determine the earliest agreeable date.
To promote efficient management of formal meetings, the requestor should try to anticipate future needs and, to the extent practical, combine product development issues into the fewest possible meetings. Generally, we will not grant more than one of each of the Type B meetings for each potential application (e.g., investigational new drug application (IND), new drug application (NDA), biologics license application (BLA)) or combination of closely related products developed by the same sponsor or applicant (e.g., same active ingredient but different dosage forms being developed concurrently), but we can do so when it would be beneficial to hold separate meetings to discuss unrelated issues. It also may be appropriate to conduct more than one of some of the Type B meetings for concurrent development of a product for unrelated claims.
Hi C! I was expecting this to be a quiet year for PIRS so this has been a very welcome surprise. I've sold a few to build more V_GN. Also bought RL_D when it was in the 60s. Love both of those for ketamine-effect antidep plays....Hope you are well C and having a great summer!
Thank you C!
OpenText To Acquire Covisint
PR Newswire PR Newswire Follow Jun 5, 2017 4:21 PM EDT
Get TheStreet Quant Ratings' exclusive 5-page report for (COVS) - FREE.
Acquisition to Strengthen IoT and Automotive Digital Supply Chain
WATERLOO, Ontario, June 5, 2017 /PRNewswire/ -- OpenText™ (NASDAQ: OTEX) (TSX: OTEX), a global leader in Enterprise Information Management (EIM), announced today that it has entered into a definitive agreement to acquire Covisint Corporation (NASDAQ: COVS), the leading Cloud platform for building Identity, Automotive, and Internet of Things (IoT) applications.
OpenText logo. (PRNewsFoto/OpenText)
The acquisition is expected to deepen OpenText's EIM offering with a cloud-based IoT platform-as-a-service and expand OpenText's presence in the Automotive industry through strong customer relationships and strategic partnerships for supply chain collaboration. Covisint will be integrated into the OpenText Business Network, a portfolio of cloud solutions and software that facilitates efficient, secure, and compliant information flows between organizations.
Terms of the Agreement The transaction purchase price of $2.45 per share is approximately $103 million of market value, or $75 million of enterprise value. OpenText intends to fund the transaction with cash on hand. The transaction is expected to close in the third quarter of calendar 2017 and is subject to customary closing conditions, including approval by shareholders of Covisint. (1)
About OpenText OpenText enables the digital world, creating a better way for organizations to work with information, on premises or in the cloud. For more information about OpenText (NASDAQ: OTEX, TSX: OTEX) visit
Great buy-out candidate here C!
Signs of life! Good to see after such a long and tough time!
I know. I keep hearing a funeral dirge every time I look at SYN.
I'm still here C! Hard to see the beating SYN has taken lately, but I'm still in and glad to see you and our favorite canine lovers (Hi Boodog! Hi TheHound!)are in too. Never thought anyone would have the chance to buy in so low. Glad for everyone who did while sorry for the pulverized sp at the same time!
I have been smiling today C! Thanks for the post. I sold some today and will rebuy when it tires out again. Have a great weekend Citrati!
Hi Citrati! I've been in New Orleans for the past couple of weeks and am just catching up on posts. My thoughts are that SYN will trial both drugs successfully thru ph3 and FDA approval. Very unusual for a small biotech to pull that off but I think they will. Finances continue to be a concern, to all of us I'm sure. They need a 1 or 2 partnerships desperately.
Ya. Buy the run-up and sell on the news. Crossing my fingers for that same solid floor.
Maybe just the markets lack of vision. We've been here for CDI prevention and we know how important and big 004 will be if the microbiome protective effect is significant. But Mr.Market really liked the AAD endpoint and may be showing his disappointment in those results right now. CDI goal is looking great. If development continues to prove that goal, 004 is a winner. It just might take a while for the larger investment community to recognize that.
Covisint Launches Supplier Engagement Platform for SAIC General Motors and NextEV in China
GlobeNewswire•December 7, 2016Comment
DETROIT and SHANGHAI, China, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Covisint Corporation (COVS) today announced that it has signed agreements with Chinese automotive OEMs, SAIC General Motors (SGM) and NextEV to launch supplier engagement platforms for each of their global enterprises.
The Covisint platform provides the foundation for SAIC General Motors (SGM) and NextEV to provide easy access to critical applications and content to their ecosystem of suppliers, regardless of size or location, and enable both SAIC General Motors and NextEV to realize the following benefits:
Extend their enterprise to manage external supplier users with single sign-on to critical resources based on user types.
Delegated administration both for security and access, as well as for content management and collaboration resources.
Manage, automate and govern the complex network of people, systems, and things that need access to resources.
Authenticated and unauthenticated content that can be personalized and presented to users based upon attributes such as location, division and role.
Anytime, anywhere support with industry-leading service level agreements and availability.
"Innovative, high-growth companies like SGM and NextEV recognize the need for a single, global platform to meet their next generation supply chain needs," said Steve Asam, CTO, Covisint. "We are proud to expand our global platform to enable the first and only Automotive Exchange to be hosted in China."
Established in June 1997, SAIC General Motors (SGM) is a joint venture between SAICMOTOR and General Motors, and is the largest automotive OEM in China. Today, SGM is a multi-brand company with more than twenty product lines, including the world-renowned Buick, Chevrolet, and Cadillac brands, covering the luxury, compact, sedan, MPV, and SUV segments, as well as hybrid and electric vehicles. They expect over 5,000 suppliers to be connected to the platform in the near future.
Covisint was recognized as supplier of the year by SAIC GM in 2016 and was the sole IT supplier to receive this award.
NextEV is the newest Chinese electric vehicle OEM headquartered in San Jose and has over 2,000 employees across 12 countries. NextEV released the NIO brand, as well as model EP9 as the first ultra-pure electric vehicle in China on November 21, 2016.
"Covisint is the leader in providing automotive supply chain solutions in China, as our global network continues to grow," said Yan Zhang, General Manager of Asia Pacific Operations for Covisint. "This continued growth in China validates the value our platform delivers."
SAIC General Motors and NextEV join the world`s largest automotive supplier network, which has over 97,000 suppliers globally connected to 7 global OEMs. Over 600,000 supplier users access more than 700 applications and services across these OEMs. The community is multi-lingual available in over 10 languages and with 24x7x365 help desk support in 6 global locations.
About Covisint Corporation
Covisint is the leading Cloud Platform for building Identity and Internet of Things (IoT) applications. Our Cloud Platform technology facilitates the rapid development of identification, authorization and connection of complex networks of people, processes, systems and things.
The Covisint Cloud Platform supports customers in their endeavors to securely identify, authenticate and connect users, devices, applications and information. It supports 2,000 organizations who connect more than 212,000 business partners and customers that support $4 billion in ecommerce transactions annually. Learn more at www.covisint.com.
https://finance.yahoo.com/news/covisint-launches-supplier-engagement-platform-220201013.html
I read it. Good post. Couple of things incorrect though. Riley didnt know Trimesta was going to fail. I don't think he liked having it as legacy trial when he took over the company, but he had the same info we all did and definite failure wasn't indicated. Also, it is likely that there were interested parties and discussions occurring. External partnership inquiries likely included waiting until the trial results with MRI translations were finished before serious offers made. Buying blind to that pending info would have been an act of naivete uncommon to biotech.
Also, the CDC does not have a role of pushing drugs to FDA for approval purposes. So, there is no scenario where CDC will assist in 004s approval other than its enhancement of 004 evidence pool thru knowlege gained with current grant.
Other than those small things, I think the post was well thought out and presents some possible scenarios.
In with goal of near term buy-out.
I've been stunned into silence by this offering. Feels like management gave us all the finger. Yes, they have some go-it-alone $ for their upcoming trials. And they need it. I'm still in but watching management with a more skeptical eye.
Not much to say C. Author kept it simple, direct and did a good job. I think SYN has a good chance of proving preventative efficacy with this 400 patient population, but I'd have loved 1000 with some known hot zone hospitals chosen. Still, SYN management moves methodically and carefully. They've done well so far and I'm thinking they have this covered.
And green to you too Citrati! Thank you!
People are going a little crazy about this award. Rumors flying. It will support and enhance an area of research SYN had to do anyway, so big help there. But the CDC won't push 004 thru ph3 and FDA approval. Not the purpose of this award. The CDC did not get an early peek at undisclosed pending 2b 004 results before awarding this contract. The application was done in the spring and such info was unavailable, never mind the fact that such a move would be unethical and a credibility ruination for the company. The award was split between multiple applicants. Its not a huge amount of money. They haven't partnered with the CDC for 004 development.
They have a beneficial contract with the CDC that offers some financial support in researching 004 effect on the microbiome. It is a collaborative contract, meaning there will be exchange of information, which may include some of SYN's emerging intellectual property portfolio of 004. The contract surely protects SYN in this information exchange while adding to the CDC's intellectual research base. Its a great thing for both parties...but it's not the miraculous event some of todays message board posters are imagining.
I didn't know they were applying for this. The app was due May 6,16. Here is full CDC description of requirements for application: https://govtribe.com/project/advanced-and-innovative-solutions-to-improve-public-health-broad-agency-announcement OADS_Broad_Agency_Announcement_Amendment__1.docx.
It's no wonder SYN won the contract. As you can see, it looks tailor-made for them.
This statement "The Company will examine DNA isolated from longitudinal samples obtained during the clinical trial and look for changes to the patient's gut resistome, specifically examining for alterations in the presence and/or abundance of antibiotic resistance genes" shows that the information derived from this supported research will be applicable to 004 and 006 and 007. So SYN benefits beyond the specific 004 award. The application had to be peer reviewed by a group of CDC scientists, adding more credibility to the quality of SYN's research. It's most likely not a lot of money, but it's a very positive thing that they won the contract.
Well....at least now they can trial PRS-343 without financial worries and with the ability to choose to partner at a very good price since they won't be cash strapped. 343 going into ph1 first half 2017. If results are decent, it will attract a lot of attention. PIRS can evaluate suitors from a position of strength, not weakness.
Could easily move above 2. It has before. But unlikely to sustain that sp becuase theres going to be a news drought.
Can't see reason for dilution. They're well funded. They could surprise me though.
Absolutely massive volume for PIRS today. Biggest day so far this calendar year. More than a million shares traded today. Worth paying attention to.
VTGN is now a one trick pony pipeline/company. It is an oral ketamine play,and a good one. Just ignore the company description on the VTGN ihub page. Its outdated and no longer applicable.
This is big news everyone, even though its still preclinical.
http://www.pieris.com/news-and-events/press-releases/detail/543/pieris-pharmaceuticals-presents-positive-data-for-its-lead
PIERIS PHARMACEUTICALS PRESENTS POSITIVE DATA FOR ITS LEAD BISPECIFIC DRUG CANDIDATE, PRS-343, AT THE 2016 CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE
Download PDF
NOVEL 4-1BB/HER2 BISPECIFIC DEMONSTRATES DIFFERENTIATION OVER CONVENTIONAL 4-1BB MAB AND HER2 MAB APPROACHES
BOSTON, MA -- (Marketwired) -- 09/26/16 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference - Translating Science into Survival, taking place in New York City.
The in vivo data show that treatment of HER2-positive tumor-bearing animals with PRS-343 provided dose-dependent, dual anti-tumor activity by increasing the frequency of tumor-infiltrating lymphocytes via bispecific targeting of 4-1BB and HER2, as well as mediating tumor growth inhibition by direct antagonism of HER2 on tumor cells. In contrast, an agonistic anti-4-1BB benchmark monoclonal antibody (mAb) displayed neither tumor growth inhibition nor enhanced lymphocyte infiltration into tumors compared to an isotype control mAb, but preferentially activated T cells systemically, resulting in significant toxicity. A copy of the poster can be viewed and downloaded by clicking http://www.pieris.com/pirs-cri-poster-2016.
Buying.
Oh! That's some happy-chart happenings!
Thank you Citrati! I logged on to ask you the very question you answered with your chart. As usual, weighing lock in of profits points. Figure we'll have a couple of decent runs in the next 6 weeks with news anticipation. Your analysis is always especially helpful in situations like this one!
Todays volume supports your feeling. Higher than its been in months.
We've been way patient with this one! It'll be nice to see some serious green.
Agree!
Thanks for that. I'll check it out.
Hi C! I dont follow cytk too closely but they look good going into this ph3. Nothings changed so no reason for sp to have dipped so much. Read a post that said people were upset at no mention of SPA but so what? Amgen is not going to design poor measurable endpoints on an expensive phase 3 so no SPA isnt any kind of dealbreaker. Looks like good dip for buyers to me.
Thank you Citrati!
Getting their act together finally. If they continue executing this way,they will be a success.
http://ir.stockpr.com/mriinterventions/company-news/detail/912/mri-interventions-announces-6-million-private-placement
Well NR, it's on my possible acquisition list second only to VTGN. Third on list right now is HPPI and 4th is RVVTF...
We were all so young and innocent then....:)
I'm way ahead of ya! Have the palanquin ready and uniforms for the palanquin bearers....who strangely and coincidentally all look like the Rock....Happy day!
I think this is a done deal. Company says 'signed definitive agreement' and 'unanimous BoD approval'. Don't think other offers will be entertained.